Anogenital Warts
9
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
The Role of Genital Warts in HIV Acquisition in Peru
Evaluation of Long Term Immunity Following HPV Vaccination
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers